FDA warns Dr. Evelyn Lopez-Brignoni over inadequate dosing in pediatric investigational drug trials.
What happened
FDA inspected the clinical site from June 8 to June 23, 2020, as part of its Bioresearch Monitoring Program and reviewed the site’s July 7, 2020 response. FDA found that two pediatric protocols required specific study-drug dosing, but subjects received less than the required dose; some may have received placebo only or less than the full intended dose. FDA said this raises concerns about subject safety and the validity and integrity of the data.
What FDA found
The investigator did not ensure the clinical investigations were conducted according to the investigational plan.
21 CFR 312.60In the two pediatric studies, subjects did not receive the required study-drug dosing, and some may have received placebo only or less than the full intended dose.
21 CFR 312.60FDA said the majority of randomized subjects did not receive sufficient dosing to support the studies’ primary objectives, raising concerns about data validity and integrity.
21 CFR 312.60
What FDA wants
Within 15 working days of receiving the letter, the investigator should write to FDA describing actions taken to prevent future violations. FDA also asks the investigator to specify the corrective actions taken as clinical investigator, not only site-staff actions.
Who should pay attention
- clinical research sites running pediatric trials
- sponsors and CROs monitoring investigator-led studies
- IRBs and research compliance teams
This is a summary. Read the original letter on fda.gov.